<DOC>
	<DOCNO>NCT03055611</DOCNO>
	<brief_summary>Elocta ( rFVIIIFc ) Alprolix ( rFIXFc ) recombinant extend half-life coagulation factor product . The purpose non-interventional study describe real-world usage effectiveness Elocta Alprolix prophylactic treatment haemophilia A B .</brief_summary>
	<brief_title>A Study Evaluate Real-world Usage Effectiveness Elocta Alprolix Patients With Haemophilia A B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Have diagnosis haemophilia A B previously treat factor Product Have start prophylactic Elocta/Alprolix treatment within 3 month prior enrollment visit , enrollment prescribe prophylactic treatment Elocta Alprolix regardless participation study Signed date informed consent provide patient , patient 's legally acceptable representative patient legal age , Before studyrelated activity undertake . Assent obtain paediatric patient accord local regulation . Enrollment concurrent Clinical interventional study involve intake investigational Product ( IMP ) , within Three month prior enrollment visit .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Blood Coagulation Disorder</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Coagulation Protein Disorder</keyword>
	<keyword>Hemorrhagic Disorder</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
</DOC>